Status:
TERMINATED
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Lead Sponsor:
Karyopharm Therapeutics Inc
Conditions:
Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have rela...
Detailed Description
This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced rel...
Eligibility Criteria
Inclusion
- 18 years of age or older
- confirmed SCC of the head and neck, lung, or esophagus
- 1 to 2 prior therapies
- measurable disease at screening and documented progression within the past 6 weeks
Exclusion
- patients requiring total parenteral nutrition
- unstable cardiovascular function
- substantially impaired gastrointestinal function
- Symptomatic brain metastases
- another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer
Key Trial Info
Start Date :
September 22 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2015
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT02213133
Start Date
September 22 2014
End Date
December 10 2015
Last Update
January 26 2023
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
2
Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
3
Northwestern University
Evanston, Illinois, United States, 60208
4
Tufts Medical Center
Boston, Massachusetts, United States, 02111